A 'mild' COVID-19 case just means you don't end up in the hospital, epidemiologists caution

There was good news and bad news about COVID-19 and its Omicron variant on Tuesday.

U.S. health officials said the new variant is spreading fast and will soon become the dominant coronavirus strain in the U.S., demoting Delta, but Pfizer announced that its new antiviral drug Paxlovid has proved extremely effective at keeping high-risk COVID-19 patients alive and out of the hospital, and appears to work against the Omicron variant. A South African study found that two doses of Pfizer's vaccine was only 33 percent effective against Omicron infection and 70 percent effective at preventing hospitalization and death, but also that the illness from this new variant appears more mild than with previous strains.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
Peter Weber, The Week US

Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.